One amyloid candidate left for Biogen, Eisai after axing BACE trials

Despite ending two Phase III trials of BACE inhibitor elenbecestat Friday, Biogen and Eisai have not walked away from the amyloid hypothesis of Alzheimer’s disease. The partners' Phase III trial of anti-amyloid mAb BAN2401 forges on, treating about 1,600 more patients with an amyloid agent.

Biogen Inc. (NASDAQ:BIIB) and Eisai

Read the full 504 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE